InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (3 ops.)
Insider track record
ExecutiveDisclosed buys
2
Disclosed sells
3
T+90 hit rate
0%
T+90 mean return
-37.5%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Shah Jatin, Vice-Président Exécutif. Director active across 1 company, notably Karyopharm Therapeutics Inc.. Cumulatively, 7 filings have been logged. Breakdown: 2 buys · 3 sells. Total volume traded: €375k. Activity tracked since 7 May 2021. The latest transaction was filed on 17 February 2022 (Cession). Regulator: SEC (Form 4). The full history is openly available.
Declarations7 total
1,306 shares@ US$12.12340.0080% mcap3.6% of flowCommon StockSEC:0001209191-22-011650:0
1,704 shares@ US$9.8620.0084% mcap3.8% of flowCommon StockSEC:0001209191-22-008130:0
1,704 shares@ US$9.8620.0084% mcap7.9% of flowCommon StockSEC:0001209191-22-008130
665 shares@ US$9.731.4% of flowCommon StockSEC:0001209191-21-046589
665 shares@ US$9.730.0031% mcap1.4% of flowCommon StockSEC:0001209191-21-046589:0
23,250 shares@ US$8.60180.095% mcap43.0% of flowCommon StockSEC:0001209191-21-031481:0
Ideal exit: 1 Feb 2022 (T+270)
23,250 shares@ US$8.601843.0% of flowCommon StockSEC:0001209191-21-031481
Ideal exit: 1 Feb 2022 (T+270)
7 of 7 declarations
About Shah Jatin
Jatin Shah is the Executive Vice President and Chief Medical Officer at Karyopharm Therapeutics Inc., a biopharmaceutical company. He oversees medical and research initiatives aimed at developing new treatments for patients.
